Interpace Biosciences, Inc. (IDXG)
OTCMKTS · Delayed Price · Currency is USD
1.750
-0.010 (-0.57%)
Jun 3, 2026, 3:56 PM EST
Interpace Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 23.65 | 24.58 | 6.7 | 1.95 | -21.96 | -14.94 |
Depreciation & Amortization | 0.82 | 0.82 | 0.75 | 1.6 | 3.5 | 5.37 |
Other Amortization | 0.06 | 0.06 | - | 0.04 | 0.06 | 0.12 |
Loss (Gain) From Sale of Assets | - | - | - | - | -0.07 | 0.06 |
Asset Writedown & Restructuring Costs | 0.2 | 0.2 | - | - | 12.4 | - |
Stock-Based Compensation | 0.04 | 0.04 | 0.29 | 0.63 | 1.3 | 1.37 |
Provision & Write-off of Bad Debts | - | - | - | - | - | -0.14 |
Other Operating Activities | -21.17 | -21.14 | 0.58 | 0.8 | 1.07 | 0.57 |
Change in Accounts Receivable | 2.9 | 2.9 | -3.47 | 0.23 | -0.13 | 2.15 |
Change in Accounts Payable | -0.81 | -0.81 | 0.12 | 0.49 | -0.74 | -1.82 |
Change in Other Net Operating Assets | -0.8 | -0.8 | -0.33 | -1.95 | -3.12 | -1.46 |
Operating Cash Flow | 4.88 | 5.83 | 4.65 | 3.79 | -7.69 | -8.72 |
Operating Cash Flow Growth | -17.85% | 25.51% | 22.62% | - | - | - |
Capital Expenditures | -0.36 | -0.36 | -0.88 | -0.47 | -0.32 | -0.35 |
Sale of Property, Plant & Equipment | - | - | - | - | - | 0.04 |
Other Investing Activities | -0.14 | - | - | 0.38 | 6.53 | - |
Investing Cash Flow | -0.5 | -0.36 | -0.88 | -0.09 | 6.21 | -0.32 |
Short-Term Debt Issued | - | - | - | - | 2 | 7.5 |
Long-Term Debt Issued | - | - | - | - | 1 | 9.5 |
Total Debt Issued | - | - | - | - | 3 | 17 |
Short-Term Debt Repaid | - | - | - | - | - | -7.92 |
Long-Term Debt Repaid | - | -4.4 | -5.6 | -2.5 | - | - |
Total Debt Repaid | -4.4 | -4.4 | -5.6 | -2.5 | - | -7.92 |
Net Debt Issued (Repaid) | -4.4 | -4.4 | -5.6 | -2.5 | 3 | 9.08 |
Issuance of Common Stock | - | - | - | - | 0.11 | 0.34 |
Repurchase of Common Stock | -0.02 | -0.02 | -0.05 | -0.03 | -0.11 | - |
Other Financing Activities | 1.49 | -0.01 | -0.16 | -2.5 | - | -0.44 |
Financing Cash Flow | -2.93 | -4.43 | -5.81 | -5.03 | 3 | 8.98 |
Net Cash Flow | 1.45 | 1.04 | -2.04 | -1.33 | 1.51 | -0.06 |
Free Cash Flow | 4.52 | 5.48 | 3.77 | 3.32 | -8.01 | -9.07 |
Free Cash Flow Growth | -11.16% | 45.23% | 13.59% | - | - | - |
Free Cash Flow Margin | 12.48% | 14.14% | 8.03% | 8.29% | -25.17% | -27.40% |
Free Cash Flow Per Share | 0.16 | 0.20 | 0.24 | 0.76 | -1.89 | -2.19 |
Cash Interest Paid | 0.17 | 0.17 | 0.63 | 1.09 | 0.97 | 0.42 |
Cash Income Tax Paid | 0.1 | 0.1 | 0.01 | 0.27 | 0.25 | 0.37 |
Levered Free Cash Flow | 4.64 | 5.09 | 1.41 | -1.19 | -0.03 | 1.78 |
Unlevered Free Cash Flow | 4.63 | 5.14 | 1.82 | -0.6 | 0.54 | 2.31 |
Change in Working Capital | 1.29 | 1.29 | -3.68 | -1.24 | -3.99 | -1.13 |